Immune checkpoint inhibitors (ICIs) are widely used for various malignancies. However,
their safety and efficacy in patients with a kidney transplant have not been defined. To …

Introduction Kidney transplant (Ktx) recipients are excluded from clinical trials of immune
checkpoint inhibitors. The aim of this systematic review was to assess the safety of immune …

Background Most kidney transplant recipients with cancer stop or reduce
immunosuppressive therapy before starting treatment with an immune checkpoint inhibitor …

Limited data exist on safety and efficacy of immune checkpoint inhibitors (ICIs) among organ
transplant recipients. The objective of this study was to report a case series of two patients …

Immunologic control of malignancy has long been recognized as an important determinant
of disease progression. Recent advances in immunology have led to the focus on several …

Background Solid organ transplant recipients are at increased risk of cancer due to long-
term immunosuppression. Immune-checkpoint inhibitors (ICI) showed clinical benefits but …

Chronic immunosuppression in solid organ transplant recipients (SOTRs) leads to an
increased risk of a wide variety of cancers. Immune checkpoint inhibitor (ICI) therapy is …

Solid organ transplant (SOT) is frequently complicated by cancers, which render
immunosuppression challenging. Immune checkpoint inhibitors have emerged as …

Immune checkpoint inhibitors have been approved for a variety of cancer species. Renal
complications in use of these agents are not very common compared with other immune …

Renal toxicities have been increasingly recognized as complications of the immune
checkpoint inhibitors (ICIs). Recent studies have outlined the incidence and potential risk …